Drugs / SCR-6920
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05528055 | May 2022 → Oct 2027 expected | cancer, non-Hodgkin lymphoma | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-03-23 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory Simcere’s oral PRMT5 inhibitor obtained IND Approval from NMPA simcere.com ↗ |
| 2022-01-26 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory IND of a novel oral PRMT5 inhibitor for the treatment of advanced malignant tumors accepted by NMPA simcere.com ↗
In January 12, 2022, Simcere announces that the IND of a novel oral PRMT5 inhibitor (project number: SIM0272, product code: SCR-6920) in China for the treatment of advanced malignant tumors was accepted by NMPA. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-03-23 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Simcere’s oral PRMT5 inhibitor obtained IND Approval from NMPA simcere.com ↗ |
| 2022-01-26 | Jiangsu Simcere Pharmaceutical Co., Ltd. | IND of a novel oral PRMT5 inhibitor for the treatment of advanced malignant tumors accepted by NMPA simcere.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCR-6920 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05528055 ↗ |
| Action | Inhibit | “PRMT5 inhibitor” NCT05528055 ↗ |
| Route | Oral | “SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis” NCT05528055 ↗ |
| Target | PRMT5 | “PRMT5 inhibitor” NCT05528055 ↗ |